CKD affects a significant proportion of the world's population, and the prevalence of CKD is
increasing. Standard practice currently is to adjust the dose of renally eliminated …

Chronic kidney disease (CKD) has become a global public health problem with high
morbidity and mortality. Renal fibrosis can lead to end-stage renal disease (ESRD) …

This article is a report on a symposium sponsored by the American Society for
Pharmacology and Experimental Therapeutics and held at the Experimental Biology 07 …

Drug pharmacokinetics (PK) is influenced by multiple intrinsic and extrinsic factors, among
which concomitant medications are responsible for drug–drug interactions (DDIs) that may …

Kidney disease not only alters the renal elimination but also the non-renal disposition of
drugs that are metabolized by the liver. Indeed, modifications in the expression and activity …

Introduction: Scientific interest in the gut microbiota is increasing due to improved
understanding of its implications in human health and disease. In patients with kidney …

We characterized the impact of chronic kidney disease (CKD) on the cytochrome P450
(CYP) 3A4–mediated metabolism of saxagliptin to its metabolite, 5‐hydroxysaxagliptin …

Patients with kidney dysfunction exhibit distinct pharmacokinetic profiles compared to those
with normal kidney function. Hence, it is desirable to monitor the drug efficacy and toxicity …

Background: Chronic Kidney Disease (CKD), a global public health problem, affects
numerous people worldwide, and the prevalence is rising. Results from animal experiments …

Pharmacokinetic drug–drug interactions (in particular at metabolism) may result in fatal
adverse effects in some cases. This basic information, therefore, is needed for drug therapy …